Gordon A C, McDonald C F, Thomson S A, Frame M H, Pottage A, Crompton G K
Respiratory Unit, Northern General Hospital, Edinburgh, U.K.
Eur J Respir Dis. 1987 Jul;71(1):10-4.
Increasing dose of budesonide, each dose given for a minimum of 1 month, were administered via a Nebuhaler to 14 patients. Two consecutive abnormally low fasting morning plasma cortisol values, taken 2 weeks apart, were accepted as evidence of hypothalamo-pituitary-adrenal (HPA) hypofunction. Data from nine of the 14 patients entering the study were available for analysis. One patient developed HPA hypofunction while inhaling 2.4 mg budesonide per day and another retained normal HPA function on a dose of 12 mg. In the remaining patients, intermediate doses resulted in suppression, or the patients were withdrawn unsuppressed for other reasons (n = 3). The results in this small patient sample suggest that budesonide administered via the Nebuhaler in doses up to 1.6 mg daily does not significantly affect plasma cortisol.
通过Nebuhaler给14例患者递增剂量的布地奈德，每个剂量至少给药1个月。相隔2周连续两次空腹晨血浆皮质醇值异常低被视为下丘脑 - 垂体 - 肾上腺（HPA）功能减退的证据。进入该研究的14例患者中有9例的数据可用于分析。1例患者在每天吸入2.4mg布地奈德时出现HPA功能减退，另1例患者在12mg剂量时HPA功能保持正常。其余患者中，中等剂量导致抑制，或因其他原因未被抑制而退出研究（n = 3）。这个小患者样本的结果表明，通过Nebuhaler给予的布地奈德每日剂量高达1.6mg不会显著影响血浆皮质醇。
